NCT04069936 - Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 15, 2019

Primary Completion Date

October 28, 2021

Study Completion Date

November 30, 2021

Conditions

Non Small Cell Lung CancerLung CancerLung Cancer MetastaticLung Cancer, Non-small CellNon Small Cell Lung Cancer MetastaticNSCLCNon-small Cell Lung CancerNon-small Cell Lung Cancer Metastatic

Interventions

BIOLOGICAL

MILs™ - NSCLC

To evaluate the safety of MILs™ - NSCLC alone in subjects with locally advanced and unresectable or metastatic NSCLC

BIOLOGICAL

nivolumab

To evaluate the efficacy of MILs™ - NSCLC in combination with nivolumab in subjects with locally advanced and unresectable or metastatic NSCLC

DRUG

tadalafil

To evaluate the efficacy of MILs™ - NSCLC in combination with nivolumab with or without tadalafil in subjects with locally advanced and unresectable or metastatic NSCLC

Trial Locations (10)

19111

Fox Chase Cancer Center, Philadelphia

30322

Emory University, Atlanta

33612

Moffitt Cancer Center, Tampa

37203

Sarah Cannon Research Institute, Nashville

44195

Cleveland Clinic, Cleveland

48201

Karmanos Cancer Center, Detroit

63110

Washington University, St Louis

68198

University of Nebraska Medical Center, Omaha

90095

University of California - Los Angeles, Los Angeles

91010

City of Hope, Duarte